NCT01188915Terminated
Personalised Program for Women Treated for Hodgkin Disease
Personalised Program for Women Treated for Hodgkin Disease : Risk Evaluation of Breast Cancer and Intensive Screening Program for Women at High Risk of Breast Cancer. PROPER/IPC 2010-001
Source: ClinicalTrials.gov · Last updated 14 Oct 2016
Reason given: Sponsor decision
Brief summary (registry, in English)
After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death. The investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and RMI.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 24 Aug 2010
- Start date
- Jul 2010
- Primary completion date
- Sept 2016
- Lead sponsor
- Institut Paoli-Calmettes
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT01188915
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients unable to have a regular follow-up
Who the study is looking for
- women > 18 years
- treated for Hodgkin disease
- signed informed consent
- high risk of breast cancer
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| François EISINGER, PhD | Marseille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.